Key result
A quantitative risk-based approach incorporating clinical tools, biomarkers, and genomics can help personalize risk estimation for heart failure prevention, though clinical validation is needed.
Why the study?
Targeted prevention of heart failure remains a critical need given high morbidity and mortality, requiring quantification of individual risk to guide personalized prevention strategies.
This review highlights the need for quantitative risk-based approaches, including biomarkers and genomics, to personalize heart failure prevention strategies.
No takes yet. Share an insight, caveat, or question.
Supports integrated HF risk tools in research; leaves open clinical adoption pending validation.
Sinha et al. (2021) conducted a review in Heart failure. Quantitative risk-based approach was evaluated. A quantitative risk-based approach incorporating clinical tools, biomarkers, and genomics can help personalize risk estimation for heart failure prevention, though clinical validation is needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: